ClinicalTrials.Veeva

Menu
A

AOU Maggiore Della Carita | Oncology Department

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Zanubrutinib
INCB050465
Odronextamab
BGB-3111
BGB-11417
Lenalidomide
Ifosfamide
Anastrozole
Dexamethasone
Carboplatin

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

10 of 13 total trials

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma (MAHOGANY)

The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R\^2) in participants with...

Enrolling
Relapsed/Refractory Follicular Lymphoma
Marginal Zone Lymphoma
Drug: Rituximab
Drug: Lenalidomide

This study is researching an investigational drug, odronextamab, in adult patients B-cell non-Hodgkin's lymphoma (B-NHL).The main purpose of this stu...

Enrolling
B-cell Non-Hodgkin Lymphoma (B-NHL)
Drug: Odronextamab

This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on patients with previously treat...

Enrolling
B-Cell Non-Hodgkin Lymphoma (B-NHL)
Drug: Dexamethasone
Drug: Ifosfamide

This study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide. The study is focuse...

Enrolling
Marginal Zone Lymphoma (MZL)
Relapsed/Refractory Follicular Lymphoma
Drug: Rituximab
Drug: Lenalidomide

PREcoopERA is a randomized (2:2:1), multicenter, open-label, three-arm (A, B, C), Window-of-Opportunity (WOO) trial to evaluate the activity and safe...

Enrolling
Breast Cancer
Drug: Triptorelin
Drug: Anastrozole

The purpose of this study is to evaluate the long-term safety of zanubrutinib regimens in participants with B-cell malignancies who participated in a...

Invitation-only
B-cell Malignancies
Drug: Zanubrutinib
Drug: Tislelizumab

This is a randomized study to compare the efficacy and safety of zanubrutinib plus rituximab versus bendamustine plus rituximab in previously untreat...

Active, not recruiting
Mantle Cell Lymphoma; Non-Hodgkin Lymphoma
Drug: zanubrutinib
Drug: rituximab

The study consists of two parts. Part 1 determines the safety and tolerability of BGB-11417 (sonrotoclax) monotherapy, the maximum tolerated dose, an...

Enrolling
Mantle Cell Lymphoma
Relapsed Mantle Cell Lymphoma
Drug: BGB-11417

The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versu...

Active, not recruiting
Triple Negative Breast Cancer
PD-L1 Positive
Drug: Pembrolizumab
Drug: Carboplatin

The main objective of this study is to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with...

Enrolling
CLL
Drug: Zanubrutinib
Drug: Sonrotoclax

Trial sponsors

BeiGene logo
Regeneron Pharmaceuticals logo
Incyte logo
Gilead Sciences logo
U
E

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems